We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Article |

Changing Trends in Allogeneic Bone Marrow Transplantation for Leukemia in the 1980s

Mortimer M. Bortin, MD; Mary M. Horowitz, MD; Robert Peter Gale, MD, PhD; A. John Barrett, MD; Richard E. Champlin, MD; Karel A. Dicke, MD, PhD; Eliane Gluckman, MD, PhD; Hans-Jochem Kolb, MD; Alberto M. Marmont, MD; Mirando Mrsic, MD; Kathleen A. Sobocinski, MS; Roy S. Weiner, MD; Alfred A. Rimm, PhD
JAMA. 1992;268(5):607-612. doi:10.1001/jama.1992.03490050055025.
Text Size: A A A
Published online


Objective.  —To identify changes in practice and outcome of bone marrow transplants for leukemia in the 1980s.

Design.  —Comparison of key explanatory and outcome variables in five 2-year cohorts, from 1980 through 1981 to 1988 through 1989, using a large database of detailed clinical information.

Patients.  —Recipients (7788) of bone marrow transplants for acute lymphoblastic, acute myelogenous, or chronic myelogenous leukemia reported to the International Bone Marrow Transplant Registry, Milwaukee, Wis, by 185 transplant teams worldwide.

Results.  —Linear increases occurred during the periods 1980 through 1981 to 1988 through 1989 as follows with 95% confidence intervals: (1) transplants for chronic myelogenous leukemia from 14%±2% to 35%±2%; (2) transplants from unrelated donors from 1%±1% to 7%±1%; (3) preparative regimens without radiation from 3%±1% to 30%±2%; and (4) use of methotrexate plus cyclosporine to prevent graft-vs-host disease from 2%±1% to 55%±2%. Among recipients of human lymphocyte antigen—identical sibling bone marrow, the 2-year probability of treatment-related mortality decreased by 6% to 22%. The probability of relapse decreased from 46%±6% to 38%±6% in intermediate leukemia but did not change appreciably in early or advanced leukemia. Probabilities of leukemia-free survival improved from 51%±4% to 57%±3% in early leukemia, from 28%±4% to 36%±5% in intermediate leukemia, and from 12%±4% to 18%±5% in advanced leukemia. A separate analysis of a homogenous population of patients indicated that improvements in outcome in the 1980s were due to improvements in transplant practice rather than improved patient selection.

Conclusions.  —Modest increases in leukemia-free survival rates occurred after human lymphocyte antigen—identical sibling bone marrow transplants in the 1980s. Improvements were due primarily to reductions in treatment-related mortality with little or no change in relapse risk. More effective antileukemia strategies and continued reductions in treatment-related toxic effects are needed.(JAMA. 1992;268:607-612)


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?




Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.